The impact of diabetes mellitus on outcome of patients undergoing transcatheter aortic valve replacement

IJC Metabolic and Endocrine

Volumn 9, Issue , 2015, Pages 54-60

  Minha, Sa'ar ^a   Magalhaes, Marco A ^a   Barbash, Israel M ^a   Ben Dor, Itsik ^a   Escarcega, Ricardo O ^a   Okubagzi, Petros G ^a   Baker, Nevin C ^a   Chen, Fang ^a   Torguson, Rebecca ^a   Suddath, William O ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Aortic stenosis; Diabetes mellitus; Transcatheter aortic valve replacement

Indexed keywords

HEMOGLOBIN A1C;

AGE; AGED; ARTICLE; BLEEDING; BODY WEIGHT; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; TRANSCATHETER AORTIC VALVE IMPLANTATION; VERY ELDERLY;

EID: 84942644883     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2015.05.023     Document Type: Article

References (46)

1. Preis S.R., Hwang S.J., Coady S., Pencina M.J., D'Agostino R.B., Savage P.J., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735.
2. Fang J., Alderman M.H. Impact of the increasing burden of diabetes on acute myocardial infarction in New York City: 1990-2000. Diabetes 2006, 55:768-773.
3. Akin I., Bufe A., Eckardt L., Reinecke H., Senges J., Richardt G., et al. Comparison of outcomes in patients with insulin-dependent versus non-insulin dependent diabetes mellitus receiving drug-eluting stents (from the first phase of the prospective multicenter German DES.DE registry). Am. J. Cardiol. 2010, 106:1201-1207.
4. Saleh N., Petursson P., Lagerqvist B., Skuladottir H., Svensson A., Eliasson B., et al. Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment. Diabetologia 2012, 55:2109-2117.
5. Boyne M.S., Saudek C.D. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Diabetes Care 1999, 22(Suppl. 3):C45-C53.
6. Cakmak M., Cakmak N., Cetemen S., Tanriverdi H., Enc Y., Teskin O., et al. The value of admission glycosylated hemoglobin level in patients with acute myocardial infarction. Can. J. Cardiol. 2008, 24:375-378.
7. Falcao-Pires I., Hamdani N., Borbely A., Gavina C., Schalkwijk C.G., van der Velden J., et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 2011, 124:1151-1159.
8. Katz R., Wong N.D., Kronmal R., Takasu J., Shavelle D.M., Probstfield J.L., et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-ethnic Study of Atherosclerosis. Circulation 2006, 113:2113-2119.
9. Le Tourneau T., Marechaux S., Vincentelli A., Ennezat P.V., Modine T., Polge A.S., et al. Cardiovascular risk factors as predictors of early and late survival after bioprosthetic valve replacement for aortic stenosis. J. Heart Valve Dis. 2007, 16:483-488.
10. Brown J.R., Edwards F.H., O'Connor G.T., Ross C.S., Furnary A.P. The diabetic disadvantage: historical outcomes measures in diabetic patients undergoing cardiac surgery - the pre-intravenous insulin era. Semin. Thorac. Cardiovasc. Surg. 2006, 18:281-288.
11. Halkos M.E., Kilgo P., Lattouf O.M., Puskas J.D., Cooper W.A., Guyton R.A., et al. The effect of diabetes mellitus on in-hospital and long-term outcomes after heart valve operations. Ann. Thorac. Surg. 2010, 90:124-130.
12. Lindman B.R., Pibarot P., Arnold S.V., Suri R.M., McAndrew T.C., Maniar H.S., et al. Transcatheter versus surgical aortic valve replacement in patients with diabetes and severe aortic stenosis at high risk for surgery: an analysis of the PARTNER Trial (Placement of Aortic Transcatheter Valve). J. Am. Coll. Cardiol. 2014, 63:1090-1099.
13. Adams D.H., Popma J.J., Reardon M.J., Yakubov S.J., Coselli J.S., Deeb G.M., et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N. Engl. J. Med. 2014, 370:1790-1798.
14. Grossman W., Jones D., McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest. 1975, 56:56-64.
15. Tadic M., Ilic S., Cuspidi C., Stojcevski B., Ivanovic B., Bukarica L., et al. Left ventricular mechanics in untreated normotensive patients with type 2 diabetes mellitus: a two- and three-dimensional speckle tracking study. Echocardiography Oct 7, 2014, (Epub ahead of print).
16. D'Andrea A., Padalino R., Cocchia R., Di Palma E., Riegler L., Scarafile R., et al. Effects of transcatheter aortic valve implantation on left ventricular and left atrial morphology and function. Echocardiography Oct 7, 2014, (Epub ahead of print).
17. Leon M.B., Smith C.R., Mack M., Miller D.C., Moses J.W., Svensson L.G., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 2010, 363:1597-1607.
18. Smith C.R., Leon M.B., Mack M.J., Miller D.C., Moses J.W., Svensson L.G., et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N. Engl. J. Med. 2011, 364:2187-2198.
19. Popma J.J., Adams D.H., Reardon M.J., Yakubov S.J., Kleiman N.S., Heimansohn D., et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J. Am. Coll. Cardiol. 2014, 63:1972-1981.
20. Food and Drug Administration Edwards SAPIEN Transcatheter Heart Valve (THV) Approval Letter - P110021 Available at:, (Accessed April 13, 2015). http://www.accessdata.fda.gov/cdrh_docs/pdf11/p110021a.pdf.
21. Food and Drug Administriation Edwards SAPIEN Transcatheter Heart Valve (THV) Approval Letter - P100041 Available at:, (Accessed April 13, 2014). http://www.accessdata.fda.gov/cdrh_docs/pdf10/p100041a.pdf.
22. Food and Drug Administration CoreValve Approval Letter Available at:, (Accessed April 23, 2014). http://www.accessdata.fda.gov/cdrh_docs/pdf13/P130021a.pdf.
23. Minha S., Magalhaes M.A., Barbash I.M., Ben-Dor I., Dvir D., Okubagzi P.G., et al. Impact of previous coronary artery bypass grafting on patients undergoing transcatheter aortic valve implantation for aortic stenosis. Am. J. Cardiol. 2014, 113:1222-1227.
24. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification. Eur. J. Echocardiogr. 2006, 7:79-108.
25. Du Bois D., Du Bois E.F. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 1989, 5:303-311.
26. Aguilar D., Solomon S.D., Kober L., Rouleau J.L., Skali H., McMurray J.J., et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004, 110:1572-1578.
27. Zhao W., Katzmarzyk P.T., Horswell R., Wang Y., Johnson J., Hu G. HbA1c and heart failure risk among diabetic patients. J. Clin. Endocrinol. Metab. 2014, 99:E263-E267.
28. Zhang X., Wu Z., Peng X., Wu A., Yue Y., Martin J., et al. Prognosis of diabetic patients undergoing coronary artery bypass surgery compared with nondiabetics: a systematic review and meta-analysis. J. Cardiothorac. Vasc. Anesth. 2011, 25:288-298.
29. Conrotto F., D'Ascenzo F., Giordana F., Salizzoni S., Tamburino C., Tarantini G., et al. Impact of diabetes mellitus on early and midterm outcomes after transcatheter aortic valve implantation (from a multicenter registry). Am. J. Cardiol. 2013; 2014, 113(3):529-534.
30. Tamburino C., Capodanno D., Ramondo A., Petronio A.S., Ettori F., Santoro G., et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 2011, 123:299-308.
31. Munoz-Garcia A.J., del Valle R., Trillo-Nouche R., Elizaga J., Gimeno F., Hernandez-Antolin R., et al. The Ibero-American transcatheter aortic valve implantation registry with the CoreValve prosthesis. Early and long-term results. Int. J. Cardiol. 2013, 169:359-365.
32. Pilgrim T., Stortecky S., Luterbacher F., Windecker S., Wenaweser P. Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. J. Thromb. Thrombolysis 2013, 35:456-462.
33. Alassar A., Roy D., Abdulkareem N., Valencia O., Brecker S., Jahangiri M. Acute kidney injury after transcatheter aortic valve implantation: incidence, risk factors, and prognostic effects. Innovations (Phila) 2012, 7:389-393.
34. Luciani N., Nasso G., Gaudino M., Abbate A., Glieca F., Alessandrini F., et al. Coronary artery bypass grafting in type II diabetic patients: a comparison between insulin-dependent and non-insulin-dependent patients at short- and mid-term follow-up. Ann. Thorac. Surg. 2003, 76:1149-1154.
35. Alserius T., Anderson R.E., Hammar N., Nordqvist T., Ivert T. Elevated glycosylated haemoglobin (HbA1c) is a risk marker in coronary artery bypass surgery. Scand. Cardiovasc. J. 2008, 42:392-398.
36. Medhi M., Marshall M.C., Burke H.B., Hasan R., Nayak D., Reed G., et al. HbA1c predicts length of stay in patients admitted for coronary artery bypass surgery. Heart Dis. 2001, 3:77-79.
37. Latham R., Lancaster A.D., Covington J.F., Pirolo J.S., Thomas C.S. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect. Control Hosp. Epidemiol. 2001, 22:607-612.
38. Halkos M.E., Lattouf O.M., Puskas J.D., Kilgo P., Cooper W.A., Morris C.D., et al. Elevated preoperative hemoglobin A1c level is associated with reduced long-term survival after coronary artery bypass surgery. Ann. Thorac. Surg. 2008, 86:1431-1437.
39. Sundstrom J., Lind L., Nystrom N., Zethelius B., Andren B., Hales C.N., et al. Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation 2000, 101:2595-2600.
40. Lindman B.R., Arnold S.V., Madrazo J.A., Zajarias A., Johnson S.N., Perez J.E., et al. The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis. Circ. Heart Fail. 2011, 4:286-292.
41. Stewart W.J. Regression of LV mass after transcatheter or surgical aortic valve replacement for aortic stenosis in the PARTNER I Trial. amount and predictors American Heart Association Annual Scientific Meeting 2013, (Dallas, TX).
42. Pierdomenico S.D., Lapenna D., Bucci A., Manente B.M., Cuccurullo F., Mezzetti A. Prognostic value of left ventricular concentric remodeling in uncomplicated mild hypertension. Am. J. Hypertens. 2004, 17:1035-1039.
43. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 1991, 114:345-352.
44. Van Mieghem N.M., Tchetche D., Chieffo A., Dumonteil N., Messika-Zeitoun D., van der Boon R.M., et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am. J. Cardiol. 2012, 110:1361-1367.
45. Buchanan G.L., Chieffo A., Montorfano M., Maisano F., Latib A., Godino C., et al. The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIEN and Medtronic CoreValve ReValving System® devices: the Milan registry. EuroIntervention 2011, 7:556-563.
46. Genereux P., Webb J.G., Svensson L.G., Kodali S.K., Satler L.F., Fearon W.F., et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J. Am. Coll. Cardiol. 2012, 60:1043-1052.